This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nett, J. E.
Right arrow Articles by Andes, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nett, J. E.
Right arrow Articles by Andes, D. R.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2008, p. 3411-3413, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.01656-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.

Reduced Biocide Susceptibility in Candida albicans Biofilms{triangledown}

Jeniel E. Nett,1,3 Kristie M. Guite,1 Alex Ringeisen,2 Kathleen A. Holoyda,2 and David R. Andes1,2,3*

Departments of Medicine,1 Medical Microbiology and Immunology,2 Cellular and Molecular Biology, University of Wisconsin, Madison, Wisconsin 537923

Received 21 December 2007/ Returned for modification 25 March 2008/ Accepted 12 June 2008


arrow
ABSTRACT
 
Candida biofilm formation is common during infection and environmental growth. We tested the impacts of three biocides (ethanol [EtOH], H2O2, and sodium dodecyl sulfate) on Candida albicans, C. parapsilosis, and C. glabrata biofilms. Higher concentrations of the biocides were required for efficacy against biofilms than for efficacy against planktonic controls. A combination study with two biocides (EtOH and H2O2) and fluconazole demonstrated that the combination had enhanced efficacy.


arrow
TEXT
 
Candida species cause a wide spectrum of diseases, including hospital-acquired and device-associated infections (33). In the hospital setting, Candida persists on colonized individuals and medical equipment (10). When it is growing on a surface, such as a medical device, Candida adapts to a biofilm lifestyle (14, 15, 19, 22). Biofilm formation is a common mode of growth during infection and survival in the environment (11, 15, 19, 22, 34). Biofilms consist of cells attached to a surface and embedded in a matrix produced by the organisms (13). Phenotypic changes are associated with biofilm formation, and among these, resistance to antifungal agents has been implicated in the difficulty of treatment of biofilm infections (2, 5, 21, 27, 36-38). In fact, removal of the Candida-infected medical device is nearly always required for cure of the infection (33). Biofilm resistance to antifungals has been well described (3, 4, 8, 16, 20, 37). Comparisons of biofilm cells and planktonic cells, which are the free-floating counterparts of biofilm cells, demonstrate that biofilms have up to a 1,000-fold increased resistance (8, 17, 25, 32). Candida biofilm susceptibility to biocides has received less attention. Biocides are chemical or physical agents that inactivate microorganisms. Because they commonly demonstrate a broad spectrum of activity, the agents are often used as topical therapies for patients or environmental disinfectants (12, 26, 41). Several studies of C. albicans biofilms have examined the activities of chlorhexidine, ethanol (EtOH), hydrogen peroxide, betadine, and sodium hypochlorite, although the findings have not been consistent (7, 9, 23, 42, 43, 45, 46). These investigations have not routinely included comparisons of biofilms with planktonic cell cultures. Also, experimental designs have not accounted for the difference in cell numbers between planktonic cell cultures and intact biofilms.

The purpose of this study was (i) to compare the activities of different biocides against Candida albicans, C. parapsilosis, and C. glabrata biofilm and planktonic cells and (ii) to investigate the impacts of biocides on the activity of an antifungal, fluconazole, for the prevention and treatment of Candida biofilms (C. albicans only). We chose to study EtOH, H2O2, and sodium dodecyl sulfate (SDS) because they are relatively commonly used and the have different modes of action (26). Fluconazole was selected for use in the combination therapy investigations due to the resistance of Candida biofilms to this common antifungal (3, 9, 27, 39).

C. albicans (strains DAY 185 and K1), C. parapsilosis (strain 5986), and C. glabrata (strain 5740) biofilms were grown in 96-well polystyrene plates as described previously (30, 37). The wells of the plates were inoculated with either a standard CLSI (formerly NCCLS) inoculum or a higher inoculum in RPMI- morpholinepropanesulfonic acid on the basis of the burden of viable cells in the biofilm assay at the start of therapy (106 to 107 cells/well). After 24 h of incubation at 30°C, the biofilms were washed twice with phosphate-buffered saline. For the prevention assays, the biocides were added at the time of inoculation. For the treatment assays, the biocides and fresh medium were added to mature biofilms after 24 h of biofilm growth. Dilutions of the biocides were studied to include concentrations generally effective against planktonic organisms (26). The concentration ranges studied were as follows; H2O2, 1 to 1,000 mM; EtOH, 0.05 to 50%; and SDS, 0.0004 to 0.4%. After a 24-h incubation at 30°C, a 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-2H-tetrazolium hydroxide reduction assay was performed (30, 37).

We determined the drug concentrations associated with a 50% reduction (50% effective concentration [EC50]) and an 80% reduction (EC80) in the optical density compared to that for the no-drug controls. For the studies with planktonic cells, the MICs of the biocides were measured by using CLSI endpoints. To account for the increased number of cells in the biofilm (106 to 107 CFU/well) compared to the number recommended for use in the CLSI method (0.5 x 103 to 2.5 x 103 CFU/ml), planktonic cell MICs were adjusted to a similar inoculum (18, 29). The assays were performed in triplicate on two occasions.

The impacts of the biocides in combination with fluconazole (concentration range, 0.0625 to 1,000 µg/ml) on the treatment of mature biofilms were similarly examined by using a checkerboard format. Mature biofilms (24 h) were incubated in the presence of the biocide and antifungal combination for 24 h, and the endpoints were assessed as described above. Fractional inhibitory concentration (FIC) indices were used to estimate the impact of each biocide on the activity of fluconazole, as described previously (30, 44).

EtOH, H2O2, and SDS were effective at reducing the metabolic activities of the C. albicans biofilms at concentrations commonly used for disinfection (26). However, the concentrations of the biocides required to inhibit growth were higher for biofilms than for planktonic cell cultures containing similar numbers of cells (Table 1). The concentrations needed to decrease the burden of mature biofilm cells by 50% were from 2- to 10-fold higher for biofilm cell inhibition than for planktonic cell inhibition, as follows: for EtOH, 25 to 35%; for H2O2, 125 to 250 mM; and for SDS, 0.05 to 0.15%. Decreasing the biofilm burden by 80% required even higher concentrations of EtOH and H2O2 (Table 1) (all P values were <0.05). Similarly high concentrations of EtOH and SDS were needed to prevent C. albicans biofilm formation. However, lower concentrations of H2O2 (40 mM) prevented biofilm formation (Table 1). Two of the biocides, EtOH and H2O2, potentiated the activity of fluconazole against C. albicans biofilms. However, SDS did not enhance the action of fluconazole. The positive impacts of these cell wall-perturbing agents on the activity of fluconazole along with the changes in the Candida cell wall during biofilm growth suggest a potential role for cell wall integrity in biofilm resistance (24, 30).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Effects of biocides on Candida biofilm and planktonic cellsa

These disinfectants were able to affect Candida cell viability. However, the concentrations of biocides required for efficacy against biofilm cells were greater than those associated with the killing of planktonic cells, suggesting that a reduction in susceptibility is associated with biofilms. These data suggest that concentrations higher than those previously thought necessary may be needed to disinfect contaminated medical devices and equipment. Further studies with biofilm models may be useful to determine the biocide concentrations necessary for disinfection and biofilm eradication.

EtOH and H2O2 enhancement of the activity of fluconazole may prove to be useful in the treatment and disinfection of Candida biofilms associated with medical devices and equipment. H2O2 has been used for disinfection of oral hygiene devices and contact lenses (6, 28, 40). Also, the utility of ethanol (25 to 70%) as central venous catheter lock therapy is under investigation (1, 31, 35). The current study suggests that azole drugs, such as fluconazole, may act to enhance the activities of these biocides when they are used to prevent or treat fungal biofilms.


arrow
ACKNOWLEDGMENTS
 
The project described here was supported by grant T32HL007899 from the National Heart, Lung, and Blood Institute.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Heart, Lung, and Blood Institute or the National Institutes of Health.


arrow
FOOTNOTES
 
* Corresponding author. Mailing address: Department of Cellular and Molecular Biology, Room H4/572, Clinical Sciences Center, 600 Highland Ave., University of Wisconsin, Madison, WI 53792. Phone: (608) 263-1545. Fax: (608) 263-4464. E-mail: dra{at}medicine.wisc.edu Back

{triangledown} Published ahead of print on 23 June 2008. Back


arrow
REFERENCES
 
    1
  1. Ackoundou-N'guessan, C., A. E. Heng, S. Guenu, F. Charbonne, O. Traore, P. Deteix, and B. Souweine. 2006. Ethanol lock solution as an adjunct treatment for preventing recurrent catheter-related sepsis—first case report in dialysis setting. Nephrol. Dial. Transplant. 21:3339-3340.[Free Full Text]
    2. 2
  2. Al-Fattani, M. A., and L. J. Douglas. 2004. Penetration of Candida biofilms by antifungal agents. Antimicrob. Agents Chemother. 48:3291-3297.[Abstract/Free Full Text]
    3. 3
  3. Andes, D., J. Nett, P. Oschel, R. Albrecht, K. Marchillo, and A. Pitula. 2004. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect. Immun. 72:6023-6031.[Abstract/Free Full Text]
    4. 4
  4. Baillie, G. S., and L. J. Douglas. 1998. Effect of growth rate on resistance of Candida albicans biofilms to antifungal agents. Antimicrob. Agents Chemother. 42:1900-1905.[Abstract/Free Full Text]
    5. 5
  5. Baillie, G. S., and L. J. Douglas. 2000. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J. Antimicrob. Chemother. 46:397-403.[Abstract/Free Full Text]
    6. 6
  6. Cano-Parra, J., I. Bueno-Gimeno, B. Lainez, J. Cordoba, and R. Montes-Mico. 1999. Antibacterial and antifungal effects of soft contact lens disinfection solutions. Cont. Lens Anterior Eye 22:83-86.[CrossRef][Medline]
    7. 7
  7. Chambers, S. T., B. Peddie, and A. Pithie. 2006. Ethanol disinfection of plastic-adherent micro-organisms. J. Hosp. Infect. 63:193-196.[CrossRef][Medline]
    8. 8
  8. Chandra, J., D. M. Kuhn, P. K. Mukherjee, L. L. Hoyer, T. McCormick, and M. A. Ghannoum. 2001. Biofilm formation by the fungal pathogen Candida albicans: development, architecture, and drug resistance. J. Bacteriol. 183:5385-5394.[Abstract/Free Full Text]
    9. 9
  9. Chandra, J., P. K. Mukherjee, S. D. Leidich, F. F. Faddoul, L. L. Hoyer, L. J. Douglas, and M. A. Ghannoum. 2001. Antifungal resistance of candidal biofilms formed on denture acrylic in vitro. J. Dent. Res. 80:903-908.[Abstract/Free Full Text]
    10. 10
  10. Clayton, Y. M., and G. Midgley. 1971. Estimation of dermatophytes (ringworm fungi) and Candida spores in the environment. J. Med. Microbiol. 4:P3-P4.[Medline]
    11. 11
  11. Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.[Abstract/Free Full Text]
    12. 12
  12. Cozad, A., and R. D. Jones. 2003. Disinfection and the prevention of infectious disease. Am. J. Infect. Control 31:243-254.[CrossRef][Medline]
    13. 13
  13. Donlan, R. M. 2001. Biofilm formation: a clinically relevant microbiological process. Clin. Infect. Dis. 33:1387-1392.[CrossRef][Medline]
    14. 14
  14. Douglas, L. J. 2003. Candida biofilms and their role in infection. Trends Microbiol. 11:30-36.[CrossRef][Medline]
    15. 15
  15. Douglas, L. J. 2002. Medical importance of biofilms in Candida infections. Rev. Iberoam. Micol. 19:139-143.[Medline]
    16. 16
  16. Hawser, S. P., G. S. Baillie, and L. J. Douglas. 1998. Production of extracellular matrix by Candida albicans biofilms. J. Med. Microbiol. 47:253-256.[Abstract/Free Full Text]
    17. 17
  17. Hawser, S. P., and L. J. Douglas. 1994. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect. Immun. 62:915-921.[Abstract/Free Full Text]
    18. 18
  18. Hostetler, J. S., D. W. Denning, and D. A. Stevens. 1992. US experience with itraconazole in Aspergillus, Cryptococcus and Histoplasma infections in the immunocompromised host. Chemotherapy 38(Suppl. 1):12-22.[Medline]
    19. 19
  19. Kojic, E. M., and R. O. Darouiche. 2004. Candida infections of medical devices. Clin. Microbiol. Rev. 17:255-267.[Abstract/Free Full Text]
    20. 20
  20. Kuhn, D. M., T. George, J. Chandra, P. K. Mukherjee, and M. A. Ghannoum. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773-1780.[Abstract/Free Full Text]
    21. 21
  21. Kuhn, D. M., and M. A. Ghannoum. 2004. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr. Opin. Investig. Drugs 5:186-197.[Medline]
    22. 22
  22. Kumamoto, C. A., and M. D. Vinces. 2005. Alternative Candida albicans lifestyles: growth on surfaces. Annu. Rev. Microbiol. 59:113-133.[CrossRef][Medline]
    23. 23
  23. Lamfon, H., Z. Al-Karaawi, M. McCullough, S. R. Porter, and J. Pratten. 2005. Composition of in vitro denture plaque biofilms and susceptibility to antifungals. FEMS Microbiol. Lett. 242:345-351.[CrossRef][Medline]
    24. 24
  24. Levin, D. E. 2005. Cell wall integrity signaling in Saccharomyces cerevisiae. Microbiol. Mol. Biol. Rev. 69:262-291.[Abstract/Free Full Text]
    25. 25
  25. Mah, T. F., B. Pitts, B. Pellock, G. C. Walker, P. S. Stewart, and G. A. O'Toole. 2003. A genetic basis for Pseudomonas aeruginosa biofilm antibiotic resistance. Nature 426:306-310.[CrossRef][Medline]
    26. 26
  26. McDonnell, G. E. 2007. Antisepsis, disinfection, and sterilization: types, action, and resistance. ASM Press, Washington, DC.
    27. 27
  27. Mukherjee, P. K., J. Chandra, D. M. Kuhn, and M. A. Ghannoum. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: phase-specific role of efflux pumps and membrane sterols. Infect. Immun. 71:4333-4340.[Abstract/Free Full Text]
    28. 28
  28. Muzyka, B. C. 2005. Oral fungal infections. Dent. Clin. N. Am. 49:49-65, viii.[CrossRef][Medline]
    29. 29
  29. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing. Document M27-A2, 2nd ed. NCCLS, Wayne, PA.
    30. 30
  30. Nett, J., L. Lincoln, K. Marchillo, R. Massey, K. Holoyda, B. Hoff, M. Vanhandel, and D. Andes. 2007. Putative role of β-1,3 glucans in Candida albicans biofilm resistance. Antimicrob. Agents Chemother. 51:510-520.[Abstract/Free Full Text]
    31. 31
  31. Onland, W., C. E. Shin, S. Fustar, T. Rushing, and W. Y. Wong. 2006. Ethanol-lock technique for persistent bacteremia of long-term intravascular devices in pediatric patients. Arch. Pediatr. Adolesc. Med. 160:1049-1053.[Abstract/Free Full Text]
    32. 32
  32. O'Toole, G. A. 2003. To build a biofilm. J. Bacteriol. 185:2687-2689.[Free Full Text]
    33. 33
  33. Pappas, P. G., J. H. Rex, J. D. Sobel, S. G. Filler, W. E. Dismukes, T. J. Walsh, and J. E. Edwards. 2004. Guidelines for treatment of candidiasis. Clin. Infect. Dis. 38:161-189.[CrossRef][Medline]
    34. 34
  34. Potera, C. 1999. Forging a link between biofilms and disease. Science 283:1837-1839.[Free Full Text]
    35. 35
  35. Raad, I., H. Hanna, T. Dvorak, G. Chaiban, and R. Hachem. 2007. Optimal antimicrobial catheter lock solution, using different combinations of minocycline, EDTA, and 25-percent ethanol, rapidly eradicates organisms embedded in biofilm. Antimicrob. Agents Chemother. 51:78-83.[Abstract/Free Full Text]
    36. 36
  36. Ramage, G., S. Bachmann, T. F. Patterson, B. L. Wickes, and J. L. Lopez-Ribot. 2002. Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms. J. Antimicrob. Chemother. 49:973-980.[Abstract/Free Full Text]
    37. 37
  37. Ramage, G., K. Vande Walle, B. L. Wickes, and J. L. Lopez-Ribot. 2001. Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms. Antimicrob. Agents Chemother. 45:2475-2479.[Abstract/Free Full Text]
    38. 38
  38. Ramage, G., K. VandeWalle, S. P. Bachmann, B. L. Wickes, and J. L. Lopez-Ribot. 2002. In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. Antimicrob. Agents Chemother. 46:3634-3636.[Abstract/Free Full Text]
    39. 39
  39. Ramage, G., K. Vandewalle, B. L. Wickes, and J. L. Lopez-Ribot. 2001. Characteristics of biofilm formation by Candida albicans. Rev. Iberoam. Micol. 18:163-170.[Medline]
    40. 40
  40. Rosenthal, R. A., W. M. Bell, and R. Abshire. 1999. Disinfecting action of a new multi-purpose disinfection solution for contact lenses. Cont. Lens Anterior Eye 22:104-109.[CrossRef][Medline]
    41. 41
  41. Sopwith, W., T. Hart, and P. Garner. 2002. Preventing infection from reusable medical equipment: a systematic review. BMC Infect. Dis. 2:4.[CrossRef][Medline]
    42. 42
  42. Suci, P. A., and B. J. Tyler. 2002. Action of chlorhexidine digluconate against yeast and filamentous forms in an early-stage Candida albicans biofilm. Antimicrob. Agents Chemother. 46:3522-3531.[Abstract/Free Full Text]
    43. 43
  43. Szymanska, J. 2006. Antifungal efficacy of hydrogen peroxide in dental unit waterline disinfection. Ann. Agric. Environ. Med. 13:313-317.[Medline]
    44. 44
  44. Te Dorsthorst, D. T., P. E. Verweij, J. F. Meis, N. C. Punt, and J. W. Mouton. 2004. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models. Antimicrob. Agents Chemother. 48:2007-2013.[Abstract/Free Full Text]
    45. 45
  45. Theraud, M., Y. Bedouin, C. Guiguen, and J. P. Gangneux. 2004. Efficacy of antiseptics and disinfectants on clinical and environmental yeast isolates in planktonic and biofilm conditions. J. Med. Microbiol. 53:1013-1018.[Abstract/Free Full Text]
    46. 46
  46. Webb, B. C., M. D. Willcox, C. J. Thomas, D. W. Harty, and K. W. Knox. 1995. The effect of sodium hypochlorite on potential pathogenic traits of Candida albicans and other Candida species. Oral Microbiol. Immunol. 10:334-341.[Medline]

Antimicrobial Agents and Chemotherapy, September 2008, p. 3411-3413, Vol. 52, No. 9
0066-4804/08/$08.00+0     doi:10.1128/AAC.01656-07
Copyright © 2008, American Society for Microbiology. All Rights Reserved.




This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nett, J. E.
Right arrow Articles by Andes, D. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nett, J. E.
Right arrow Articles by Andes, D. R.

Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»